EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?

Beatrice Balboni iD, Mirco Masi iD, Walter Rocchia, Stefania Girotto iD, Andrea Cavalli iD

International Journal of Molecular Sciences · 19.04.2023 · 24 (8) · 7541

DOI: 10.3390/ijms24087541 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.04.2023. Verfasst von Beatrice Balboni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Computational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Adenosine Triphosphate. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most kinase inhibitors are designed to bind to highly homologous ATP-binding sites, which leads to promiscuity and possible off-target effects. Allostery is an alternative approach to pursuing selectivity. However, allostery is difficult to exploit due to the wide variety of underlying mechanisms and the potential involvement of long-range conformational effects that are difficult to pinpoint. GSK-3β is involved in several pathologies. This critical target has an ATP-binding site that is highly homologous with the orthosteric sites of other kinases. Unsurprisingly, there is also great similarity between the ATP-binding sites of GSK-3β and its isomer, which is not redundant and thus would benefit from selective inhibition. Allostery would also allow for a moderate and tunable inhibition, which is ideal for GSK-3β, because this target is involved in multiple pathways, some of which must be preserved. However, despite considerable research efforts, only one allosteric GSK-3β inhibitor has reached the clinic. Moreover, unlike other kinases, there are no X-ray structures of GSK-3β in complex with allosteric inhibitors in the PDB data bank. This review aims to summarize the state of the art in allosteric GSK-3β inhibitor investigations, highlighting the aspects that make this target challenging for an allosteric approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsAdenosine TriphosphateGlycogen Synthase Kinase 3 betaBinding Sites

Stichwörter der Autor:innen

Alzheimer’s diseasePocketroncancerdrug discoveryinhibitors

Substanzen

Glycogen Synthase Kinase 3 betaProtein Kinase InhibitorsAdenosine Triphosphate

Autor:innen und Institutionen

  • Computational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.
  • Computational mOdelling of NanosCalE and bioPhysical sysTems (CONCEPT) Lab, Istituto Italiano di Tecnologia, Via Enrico Melen 83, 16152 Genoa, Italy.
  • Structural Biophysics and Translational Pharmacology Facility, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.

ORCID-Profile: Beatrice Balboni, Mirco Masi, Stefania Girotto, Andrea Cavalli

Zitieren

APA

Balboni, B., Masi, M., Rocchia, W., Girotto, S., & Cavalli, A. (2023). GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?. International Journal of Molecular Sciences, 24(8), 7541. https://doi.org/10.3390/ijms24087541

Vancouver

Balboni B, Masi M, Rocchia W, Girotto S, Cavalli A. GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?. International Journal of Molecular Sciences. 2023;24(8):7541. doi:10.3390/ijms24087541

BibTeX
@article{Balboni2023,
  author = {Balboni, Beatrice and Masi, Mirco and Rocchia, Walter and Girotto, Stefania and Cavalli, Andrea},
  title = {GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {8},
  pages = {7541},
  doi = {10.3390/ijms24087541}
}
Kostenlos starten →